Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Stemline Therapeutics, Inc." (STML) Report Updated: Feb 08, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Stemline Therapeutics, Inc." (STML)

Rating: Strong Sell Volatility: Conservative
Total Grade: F Industry: Biotechnology
Competitors: SVA, EXEL, ENZY, SPHS

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: F down no change
Last Week: F same downgrade
Two Weeks Ago: D up upgrade
service keys

"Stemline Therapeutics, Inc."© quotemedia

Company Profile

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary therapeutics for cancer stem cells and bulk tumors. It develops SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trials for advanced hematologic cancers; and SL-701, a vaccine that has completed two Phase I/II clinical trials for multi-epitope brain cancer. The company was founded in 2003 and is based in New York, New York.

Recent News: "Stemline Therapeutics, Inc."